Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance

Emerging Infectious Diseases

Volumn 9, Issue 1, 2003, Pages 10-16

  Stratton, Charles W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; GEMIFLOXACIN; GENTAMICIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; LINCOSAMINE DERIVATIVE; MACROLIDE; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TELITHROMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CHLAMYDOPHILA PNEUMONIAE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0037240729     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0901.020172     Document Type: Review

References (84)

1. Ashhurst AP. The centenary of Lister (1827-1927). A tale of sepsis and antisepsis. Annals of Medical History 1927;9:205-11.
2. Neu HC. Antimicrobial chemotherapy, 1934-1994. Antimicrobics and Infectious Diseases Newsletter 1994;13:1-8.
3. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
4. Levy SB. The antibiotic paradox: how miracle drugs are destroying the miracle. New York: Plenum; 1992.
5. Kunin CM. Resistance to antimicrobial drugs: a worldwide calamity. Ann Intern Med 1993;118:557-61.
6. Levy SB. Multidrug resistance - a sign of the times. N Engl J Med 1998;338:1376-8.
7. Virk A, Steckelberg J. Clinical aspects of antimicrobial resistance. Mayo Clin Proc 2000;75:200-14.
8. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8.
9. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
10. Stratton CW, Barry A, Yee YC. In vitro activity of telithromycin against clinical isolates of Streptococcus pneumoniae collected from 214 medical centers across the United States during the winter of 2000/2001. In: Posters of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Illinois; Washington: American Society for Microbiology; 2001.
11. Jacobs MR, Appelbaum, PC. Antibiotic resistant pneumococci. Rev Med Microbiol 1995;6:77-93.
12. Eliopoulos GM. Vancomycin-resistant enterococci. Infect Dis Clin North Am 1997;11:851-65.
13. Stratton CW. Mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. In: Lorian V, editor. Antibiotics in laboratory medicine, 4th ed. Baltimore: Williams & Wilkins; 1996. p. 579-603.
14. Sanders WE, Sanders CC. Do in vitro antimicrobial susceptibility tests accurately predict therapeutic responses in infected patients? In: Lorian V, editor. Significance of medical microbiology in the care of infected patients. Baltimore: Williams & Wilkins; 1982. p. 325-40.
15. Stratton CW. The clinical relevance of in vitro tests used as guidelines for antimicrobial therapy. In: Lorian V, editor. Antibiotics in laboratory medicine, 3rd ed. Baltimore: Williams & Wilkins; 1991. p. 849-79.
16. Johnson CC. In vitro testing: correlations of bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy. In: Lorian V, editor. Antibiotics in laboratory medicine, 4th ed. Baltimore: Williams & Wilkins; 1996. p. 813-34.
17. Metlay JP, Hofmann J, Cretron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
18. Bauer T, Ewig S, Marcos MA, Schultze-Werninghaus G, Torres A. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am 2001;85:1367-79.
19. Cremieux A-C, Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob Agents Chemother 1992;36:2069-74.
20. Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983;71:411-9.
21. Norden CW, Keleti E. Experimental osteomyelitis caused by Pseudomonal aeruginosa. J Infect Dis 1980;141:71-5.
22. Shyu WC, Nightingale CH, Quintiliani R. Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin alone and in combination. J Antimicrob Chemother 1987;19:807-14.
23. Weinstein MP, Stratton CW, Ackley AM, Hawley HB, Robinson PA, Fisher BD, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med 1985;78:262-9.
24. Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989;83:161-7.
25. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of the therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987;83:218-22.
26. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984;76:429-35.
27. Hilf M, Lu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
28. Cahen P, LeBoureois M, Delacourt C, Coustere C, Nicaise P, de Blic J, et al. Serum bactericidal test as a prognostic indicator in acute pulmonary exacerbations of cystic fibrosis. Pediatrics 1993;91:451-5.
29. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(Suppl 3):S38-44.
30. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001;29(Suppl 2):S 11-5.
31. Wise R. A review of the mechanisms of action and resistance of antimicrobial agents. Can Respir J 1999;6(Suppl A):A20-2.
32. Russell AD. Mechanisms of bacterial resistance to antibiotics and biocides. Prog Med Chem 1998;35:133-97.
33. Stratton CW. Mechanisms of bacterial resistance to antimicrobial agents. Lebanese Medical Journal 2000;48:186-98.
34. Musher DM, Dowell ME, Shortridge VE, Flamm RK, Jorgensen JH, Le Magueres P, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-1.
35. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
36. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40:1817-24.
37. Malbruny B, Nagai K, Coquemont M, Bozdogan B, Andrasevic AT, Hupkova H, et al. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother 2002;49:935-9.
38. Huovinen P. Macrolide-resistant group A streptococcus - now in the United States. N Engl J Med 2002;346:1243-5.
39. Hernandez-Alles S, Benedi VJ, Martinez-Martinez L, Pascual A, Aguilar A, Tomas JM, et al. Development of resistance during antimicrobial therapy caused by insertion sequence interruption ofporin genes. Antimicrob Agents Chemother 1999;43:937-9.
40. Periti P. Evolution of the bacterial dihydrofolate reductase inhibitors. J Antimicrob Chemother 1995;36:887-90.
41. Hughes DT, Russell NJ. The use oftrimethoprim-sulfamethoxazole in the treatment ofchest infections. Rev Infect Dis 1982;4:528-32.
42. Huovinen P, Sundstrom L, Swedberg G, Skold O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 1995;39:279-89.
43. Maskell JP. Sefton AM, Hall LM. Mechanisms of sulfonamide resistance in clinical isolates of Streptococcus pneumomae. Antimicrob Agents Chemother 1997;41:2121-6.
44. Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983;5(Suppl):S533-7.
45. Karchner AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983;98:447-55.
46. Carrer G, Flandrois JP, Lobry JR. Biphasic kinetics ofbacterial killing by quinolones. J Antimicrob Chemother 1991;27:319-27.
47. Little JW, Mount DW. The SOS regulatory system of Escherichia coli. Cell 1982;29:11-22.
48. Lewin CS, Howard BMA, Ratclife NT, Smith JT. Four quinolones and the SOS response. J Med Microbiol 1989;29:139-44.
49. Piddock LJV, Walters RN, Diver JM. Correlation of quinolone MIC and inhibition of DNA, RNA and protein synthesis and induction of the SOS response in Escherichia coli. Antimicrob Agents Chemother 1990;34:2331-6.
50. Piddock LJV, Walters RN. Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response for cell division. Antimicrob Agents Chemother 1992;36:819-25.
51. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
52. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
53. Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994;22(Suppl 2):S111-21.
54. Piddock LJ. Mechanisms of resistance to fluoroquinolones: state of the art 1992-1994. Drugs 1995;49(Suppl 2):S29-35.
55. Hooper DC. Bacterial resistance to fluoroquinolones: mechanisms and patterns. Adv Exp Med Biol 1995;390:49-57.
56. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 1993;37:126-7.
57. Zhanel GG, Karlowsky JA, Saunders MH, Davidson RJ, Hoban DJ, Hancock RE, et al. Development of multiple-antibiotic-resistance (mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob Agents Chemother 1995;39:489-95.
58. Goldman JD, White DG, Levy SB. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid killing by fluoroquinolones. Antimicrob Agents Chemother 1996;40:1266-9.
59. Meng X, Pei Y, Nightingale CH, Quintiliani R. Determination of the in vivo post-antibiotic effect. J Antimicrob Chemother 1995;36:987-96.
60. Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microbiol Infect Dis 2001;40:51-7.
61. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LF, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000;160:1399-408.
62. Kuehnert MJ, Note FS, Perlino CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 1999;131:312-3.
63. Davidson RJ, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
64. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993;31(Suppl C):11-26.
65. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs 1996;51(Suppl I):20-30.
66. Cocito C, di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(Suppl A):7-13.
67. Porse BT, Garrett RA. Sites of interaction of streptogramin A and B antibiotics in the peptidyl transferase loop of 23S rRNA and the synergism of their inhibitory mechanisms. J Mol Biol 1999;286:375-87.
68. Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effect and post-antibiotic sub-MIC effect to quinupristin-dalfopristin against gram-positive and -negative organisms. Antimicrob Agents Chemother 1998;42:3028-31.
69. Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 1996;51(Suppl 1):31-7.
70. Lamb HM, Figgit DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs 1999;58:1061-97.
71. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661-9.
72. Bryskier A, Agouridas C, Chantot JF. Acid stability of new macrolides. J Chemother 1993;5(Suppl 1):S158-9.
73. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000;36:183-93.
74. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40:1817-24.
75. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998;42:945-6.
76. Dever LL, Yassin HM. Related articles, links Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opinions on Investigative Drugs 2001;10:353-67.
77. Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23-9.
78. Gustafsson I, Hjel E, Cars O. In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1846-9.
79. Bryskier A. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 1998;27:865-83.
80. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA. Mol Microbiol 1999;31:623-31.
81. Xiong L, Shah S, Mauvais P, Mankin AS. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity ofhairpin 35 to peptidyl transferase centre. Mol Microbiol 1999;31:633-9.
82. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:414-7.
83. Leclercq R. Will resistance to ketolides develop in Streptococcus pneumoniae? J Infect 2002;44(Suppl A):S11-6.
84. Tait-Kamradt AG, Reinert RR, Al-Lahham A, Low DE, Sutcliffe JA. High-level ketolide-resistant streptococci. In: Posters of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001, Dec 16-19; Chicago, Illinois. Washington: American Society for Microbiology; 2001.